Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | TYK2 | P29597 | 3/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.30 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9938767 | 0.82 | NR4A2 (0.36) | NR4A2NOS3NOS2LMNASOS2 | |
| SCHEMBL20124521 | 0.81 | PIM1 (0.31) | PIM1 | |
| SCHEMBL1702732 | 0.81 | XPO1 (0.45) | NR4A2NOS3NOS2JAK2TYK2 | |
| SCHEMBL9942467 | 0.80 | PIK3CA (0.38) | PIK3C3 | |
| SCHEMBL25942133 | 0.80 | — | — | |
| SCHEMBL9972431 | 0.79 | KARS1 (0.45) | NR4A2PIM1NOS3NOS2CDK9 | |
| SCHEMBL9939693 | 0.75 | NPC1 (0.42) | — | |
| SCHEMBL20124470 | 0.71 | PIM1 (0.38) | NR4A2PIM1NOS3NOS2LMNA | |
| SCHEMBL20913324 | 0.71 | ALDH1A1 (0.41) | NR4A2NOS3NOS2GRM5SOS2 | |
| SCHEMBL9965317 | 0.71 | NOS3 (0.42) | NR4A2PIM1NOS3NOS2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651416-B1 | COMPOUNDS USEFUL FOR TREATING AIDS | ABIVAX (FR) | 2018-05-09 | — | — | EP | disclosed |
| US-9061999-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-06-23 | — | — | US | disclosed |
| US-9061999-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-06-23 | — | — | US | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080953-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2012-06-21 | — | — | WO | disclosed |
| EP-2465502-A1 | Compounds useful for treating AIDS | Société Splicos (FR) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR3, CBR1, CCR10 | NR4A2 384/4885PIM1 3423/4885CCNE1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.